Sirolimus Albumin-Bound

The shift to preclinical development comes several years after the company formerly known as Aadi Bioscience earned FDA approval for its Fyarro to treat adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors. Fresh off a pivot from commercial pharma business to preclinical biotech, Aadi Bioscience has rebranded to better match its strategic reboot.The company will henceforth be known as Whitehawk Therapeutics, it announced Tuesday. Its stock ticker will be updated accordingly: As of Wednesday, it will trade as “WHWK” on the Nasdaq, replacing the “AADI” symbol it’s held since going public in a 2021 merger with Aerpio Pharmaceuticals.The new name is aimed at better reflecting the biotech’s “evolution and focus on accelerating its portfolio of antibody drug conjugates (ADCs) with speed, agility and precision,” according to the announcement.That portfolio is comprised of a trio of ADCs that Whitehawk recently licensed from WuXi Biologics and Chinese biotech Hangzhou DAC. The company announced the deal in December, when it detailed a plan to pay $44 million upfront to license the assets, offering additional commitments of up to $265 million in development milestone payments and $540 million for commercial milestones.The three ADCs, now known as HWK-007, HWK-016 and HWK-206, are being developed as potential treatments for a range of cancers including lung and ovarian cancers and neuroendocrine tumors.“By leveraging the foundation of well-established tumor biology and integrating cutting-edge technologies, our strategy is designed to address the challenges of treating the most difficult cancers efficiently and effectively,” CEO Dave Lennon, Ph.D., said in Tuesday’s announcement. The shift to preclinical development comes several years after the company formerly known as Aadi earned FDA approval for its Fyarro to treat adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors.More recently, however, with a phase 2 solid tumor trial of the drug—then the only asset in Aadi’s pipeline—heading for failure last summer, the company halted the study and announced layoffs of 80% of its R&D workforce.By December, Aadi was apparently ready for a completely fresh start. In the same announcement detailing the ADC licensing deal, the company shared that it had also reached an agreement to sell off its Fyarro business and associated infrastructure, plus the Aadi name and trademark, to Japan’s Kaken Pharmaceutical.That divestment is still pending, but the proceeds are expected to fund Whitehawk’s operations through the end of 2028, it said Tuesday.

New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected to fund operations into 2028 enabling anticipated key clinical data readouts for its ADC assets Company shares to trade on Nasdaq under the symbol "WHWK" effective March 19, 2025 Company reports financial results for the fourth quarter and full-year 2024, and will host a conference call tomorrow, March 19 at 8:30 am ET MORRISTOWN, N.J. , March 18, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), formerly known as Aadi Bioscience, Inc., an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments, today announced it changed its name to Whitehawk Therapeutics, reflecting the Company's evolution and focus on accelerating its portfolio of antibody drug conjugates (ADCs) with speed, agility and precision. The Company's common stock will begin trading under the ticker "WHWK" effective March 19, 2025 . The three assets in the portfolio are in-licensed from WuXi Biologics and utilize HANGZHOU DAC's advanced ADC technology platform, which consists of a highly stable yet cleavable linker that delivers a Topoisomerase I (TOPO1) inhibitor payload. The platform is coupled with clinically validated tumor targets that are upregulated in high-potential cancer indications, including lung and ovarian. These assets are engineered to produce minimal off-target toxicity, with a higher therapeutic index and greater stability than first-generation predecessors. "Today marks a transformative moment as we reintroduce ourselves as Whitehawk Therapeutics – a focused oncology company combining science, strategy and execution to swiftly advance our portfolio of promising ADC assets," said David Lennon , President and CEO, Whitehawk Therapeutics. "By leveraging the foundation of well-established tumor biology and integrating cutting-edge technologies, our strategy is designed to address the challenges of treating the most difficult cancers efficiently and effectively. Our goal is to bring all three assets to IND in the next 15 months. Importantly, we believe our robust balance sheet will enable us to see these three assets through early clinical inflections. We are invigorated by the opportunity we have to overcome the limitations of first-generation ADCs to make a meaningful impact for patients." Recent Operational Highlights: All proposals were approved at the Company's Special Meeting of Stockholders on February 28, 2025 . Subsequently, the $100 million PIPE financing closed. The closing of the divestiture of Aadi Subsidiary, Inc. ("Aadi Sub") to Kaken Pharmaceuticals ("Kaken") is pending. Aadi Bioscience divided into two organizations. Upon the divestiture of Aadi Sub to Kaken, Kaken will assume ownership of Aadi Sub, including the Aadi name, trademark and the FYARRO® business. As of March 18, 2025 , the Aadi parent company has become Whitehawk Therapeutics, with a focus on its portfolio of ADC assets. Fourth Quarter and Full-year 2024 Financial Results: Cash, cash equivalents and short-term investments as of December 31, 2024 , were $47.2 million as compared to $108.8 million as of December 31, 2023 . Following closing of the strategic transactions, we expect to have cash and cash equivalents in the range of $170 million to $180 million , including the payment of the upfront and early milestones under the Wuxi ADC agreement. Total revenue for the quarter ended December 31, 2024 , was $7.2 million , and $26.0 million for the full-year ended December 31, 2024 , resulting from sales of FYARRO. Net loss for the three months ended December 31, 2024 , was $18.3 million as compared to $16.3 million for the three months ended December 31, 2023 . Net loss for the full-year ended December 31, 2024 , was $63.7 million , as compared to $65.8 million for the same period in 2023. About the ADC Portfolio HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7 expressing cancers. HWK-007 is being evaluated in IND-enabling studies. The Phase 1 trial is planned in non-small cell lung cancer and platinum resistant ovarian cancer, with potential to expand into novel indications (e.g. gastrointestinal, gynecological). HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is currently being evaluated in IND-enabling studies. The Phase 1 trial is planned in ovarian cancer, with potential to expand into additional indications (e.g. endometrial, cervical). HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin. HWK-206 utilizes a dual epitope binding, or biparatopic, approach which can potentially improve internalization and effectiveness of the ADC. HWK-206 is currently in candidate selection. The Phase 1 trial is planned in small-cell lung cancer and neuroendocrine neoplasms, where there are limited treatment options. Conference Call Information The Whitehawk management team is hosting a conference call and webcast tomorrow at 8:30 am ET ( 5:30 am PT ) to provide a corporate update and discuss results for the fourth quarter and full-year 2024. Participants may access a live webcast of the call and the associated slide presentation on the "Investors & News" page of the Whitehawk Therapeutics website at whitehawktx.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days. About Whitehawk Therapeutics Whitehawk Therapeutics is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn. Forward-Looking Statements This press release contains certain forward-looking statements regarding the business of Whitehawk Therapeutics that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to: the Company's cash runway extending into 2028; the closing of the strategic transactions, including the pending sale of Aadi Sub to Kaken and the payment of the upfront and early milestones under the Wuxi ADC agreement; the anticipated timing of the Company's development of its portfolio of ADC assets, including the expected timing regarding the commencement of IND-enabling studies; expectations regarding the beneficial characteristics, safety, efficacy, therapeutic effects and the size of the potential targeted markets with respect to the Company's ADC assets; and the sufficiency of the Company's existing capital resources and the expected timeframe to fund the Company's future operating expenses and capital expenditure requirements. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, uncertainties associated with preclinical and clinical development of the ADC portfolio, including potential delays in the commencement, enrollment and completion of clinical trials; failure to demonstrate the efficacy of the ADC portfolio in preclinical and clinical studies; the risk that unforeseen adverse reactions or side effects may occur in the course of testing of the ADC assets; the risk that one or more closing conditions to the pending sale of Aadi Sub to Kaken may not be satisfied; and risks related to the Company's estimates regarding future expenses, capital requirements and need for additional financing. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 , including under the caption "Item 1A. Risk Factors," and in Whitehawk's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Whitehawk's reports and other documents that Whitehawk has filed, or will file, with the SEC from time to time and available at www.sec.gov, including the Definitive Proxy Statement filed on January 31, 2025 . All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Whitehawk undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact:IR@whitehawktx.com AADI BIOSCIENCE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited) December 31 , December 31 , 2024 2023 Assets Current assets: Cash and cash equivalents $ 28,670 $ 62,888 Short-term investments 18,567 45,957 Accounts receivable, net 5,903 5,488 Inventory 5,311 6,427 Prepaid expenses and other current assets 2,836 3,826 Total current assets 61,287 124,586 Property and equipment, net 6,846 4,802 Operating lease right-of-use assets 787 1,169 Other assets 1,399 1,866 Total assets $ 70,319 $ 132,423 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 2,159 $ 5,898 Accrued liabilities 14,647 14,306 Operating lease liabilities, current portion 268 434 Due to licensor payable - 5,757 Total current liabilities 17,074 26,395 Operating lease liabilities, net of current portion 565 833 Other liabilities 202 - Total liabilities 17,841 27,228 Stockholders' equity: Common stock 2 2 Additional paid-in capital 385,114 374,129 Accumulated other comprehensive income 16 27 Accumulated deficit (332,654) (268,963) Total stockholders' equity 52,478 105,195 Total liabilities and stockholders' equity $ 70,319 $ 132,423 AADI BIOSCIENCE, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share data and earnings per share amounts) (Unaudited) Three months ended Twelve months ended December 31 , December 31 , 2024 2023 2024 2023 Revenue Product sales, net $ 7,239 $ 6,326 $ 25,983 $ 24,354 Total Revenue 7,239 6,326 25,983 24,354 Operating expenses Selling, general and administrative 11,051 10,345 36,749 44,549 Research and development 14,347 12,768 51,030 48,929 Restructuring charges - - 2,638 - Cost of goods sold 790 927 3,024 2,809 Total operating expenses 26,188 24,040 93,441 96,287 Loss from operations (18,949) (17,714) (67,458) (71,933) Other income (expense) Foreign exchange gain (loss) - 2 (4) (1) Interest income 676 1,500 3,925 6,400 Interest expense - (57) (154) (231) Total other income (expense), net 676 1,445 3,767 6,168 Net loss $ (18,273) $ (16,269) $ (63,691) $ (65,765) Net loss per share, basic and diluted $ (0.67) $ (0.60) $ (2.36) $ (2.44) Weighted average number of common shares outstanding, basic and diluted 27,086,979 26,965,909 27,029,942 26,917,967 View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-relaunches-as-whitehawk-therapeutics-marking-evolution-into-adc-company-302405009.html SOURCE Whitehawk Therapeutics, Inc.